PCI for Ischaemic Left Ventricular Dysfunction in 2023

Подробнее о видео

BCIS ACI 2023 – Dr Angela Hoye (Hull & East Yorkshire Hospitals, UK), is joined by Prof Rod Stables (Liverpool Heart and Chest Hospital, UK), Prof Anthony Mathur (Barts Health NHS Trust, UK) and Dr Sen Devadathan (Royal Cornwall Hospitals NHS Trust, UK) to have a critical discussion on the BCIS-REVIVED trial and what it means for patients with ischaemic left ventricular dysfunction in 2023.

Results from REVIVED-BCIS2 were announced at ESC 2022. The trial showed no benefit to revascularization by percutaneous coronary intervention (PCI) in patients with severe ischemic left ventricular systolic dysfunction, as compared with optimal medical therapy.
For a deep dive into the results watch this Late-breaker discussion with Dr Harriette Van Spall and principal investigator, Dr Divaka Perera.

00:57: Strengths and Flows of the REVIVED-BCIS2 trial
3:19: Reception of REVIVED-BCIS2 trial: Recruitment & Power
5:42: Perspectives on patient selection by participating faculty, Dr Mathur & Dr Stables
7:07: REVIVED impact on practice
9:00: Mortality rate of patients with ischemic cardiomyopathy in the REVIVED trial
11:13: REVIVED sub-studies: What data should we expect?
12:05: Assessing patients for viability for PCI
16:00: Gender representation in REVIVED
16:38: Considerations for practice in light of the REVIVED data

Recorded on-site at BCIS ACI 2023, London.

Visit Radcliffe Cardiology:

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook:
Follow us on Twitter: